|
1
|
Hehlmann R: How I treat CML blast crisis.
Blood. 120:737–747. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Druker BJ, Guilhot F, O’Brien SG, et al:
Five-year follow-up of patients receiving imatinib for chronic
myeloid leukemia. N Engl J Med. 355:2408–2417. 2006.PubMed/NCBI
|
|
3
|
Hughes TP, Kaeda J, Branford S, et al:
Frequency of major molecular responses to imatinib or interferon
alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N
Engl J Med. 349:1423–1432. 2003. View Article : Google Scholar
|
|
4
|
Randolph TR: Chronic myelocytic leukemia -
Part II: Approaches to and molecular monitoring of therapy. Clin
Lab Sci. 18:49–56. 2005.PubMed/NCBI
|
|
5
|
Druker BJ, Tamura S, Buchdunger E, et al:
Effects of a selective inhibitor of the Abl tyrosine kinase on the
growth of Bcr-Abl positive cells. Nat Med. 2:561–566. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Deininger MW, Goldman JM, Lydon N and Melo
JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits
the growth of BCR-ABL-positive cells. Blood. 90:3691–3698.
1997.PubMed/NCBI
|
|
7
|
Gambacorti-Passerini C, le Coutre P,
Mologni L, et al: Inhibition of the ABL kinase activity blocks the
proliferation of BCR/ABL+ leukemic cells and induces
apoptosis. Blood Cells Mol Dis. 23:380–394. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Druker BJ, Talpaz M, Resta DJ, et al:
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine
kinase in chronic myeloid leukemia. N Engl J Med. 344:1031–1037.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Druker BJ, Sawyers CL, Kantarjian H, et
al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase
in the blast crisis of chronic myeloid leukemia and acute
lymphoblastic leukemia with the Philadelphia chromosome. N Engl J
Med. 344:1038–1042. 2001. View Article : Google Scholar
|
|
10
|
Sawyers CL, Hochhaus A, Feldman E, et al:
Imatinib induces hematologic and cytogenetic responses in patients
with chronic myelogenous leukemia in myeloid blast crisis: results
of a phase II study. Blood. 99:3530–3539. 2002. View Article : Google Scholar
|
|
11
|
Pelloso LA, Baiocchi OC, Chauffaille ML,
Yamamoto M, Hungria VT and Bordin JO: Megakaryocytic blast crisis
as a first presentation of chronic myeloid leukemia. Eur J
Haematol. 69:58–61. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Campiotti L, Grandi AM, Biotti MG, Ultori
C, Solbiati F, Codari R and Venco A: Megakaryocytic blast crisis as
first presentation of chronic myeloid leukemia. Am J Hematol.
82:231–233. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu CD, Medeiros LJ, Miranda RN, Mark HF
and Rintels P: Chronic myeloid leukemia manifested during
megakaryoblastic crisis. South Med J. 89:422–427. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takahashi N, Miura I, Saitoh K and Miura
AB: Lineage involvement of stem cells bearing the philadelphia
chromosome in chronic myeloid leukemia in the chronic phase as
shown by a combination of fluorescence-activated cell sorting and
fluorescence in situ hybridization. Blood. 92:4758–4763. 1998.
|
|
15
|
Harris NL, Jaffe ES, Diebold J, et al:
World Health Organization classification of neoplastic diseases of
the hematopoietic and lymphoid tissues: report of the Clinical
Advisory Committee meeting-Airlie House, Virginia, November 1997. J
Clin Oncol. 17:3835–3849. 1999.
|
|
16
|
Garand R and Robillard N: Immunophenotypic
characterization of acute leukemias and chronic lymphoproliferative
disorders: practical recommendations and classifications. Hematol
Cell Ther. 38:471–486. 1996. View Article : Google Scholar
|
|
17
|
Yin T, Wu YL, Sun HP, et al: Combined
effects of As4S4 and imatinib on chronic myeloid leukemia cells and
BCR-ABL oncoprotein. Blood. 104:4219–4225. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim DH, Lee ST, Won HH, et al: A
genome-wide association study identifies novel loci associated with
susceptibility to chronic myeloid leukemia. Blood. 117:6906–6911.
2011. View Article : Google Scholar
|
|
19
|
Colla S, Sammarelli G, Crugnola M, et al:
Co-existence of Philadelphia chromosome positive acute
megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic
myeloid leukemia with chronic lymphocytic leukemia. Eur J Haematol.
72:361–365. 2004. View Article : Google Scholar
|
|
20
|
Westfall DE, Zhang L, Song S and Lee S:
Concurrent megakaryocytic and erythroid chronic myelogenous
leukemia blast crisis. Arch Pathol Lab Med. 132:1021–1025.
2008.PubMed/NCBI
|
|
21
|
Nath N, Wang S, Betts V, Knudsen E and
Chellappan S: Apoptotic and mitogenic stimuli inactivate Rb by
differential utilization of p38 and cyclin-dependent kinases.
Oncogene. 22:5986–5994. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jackman M, Lindon C, Nigg EA and Pines J:
Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat
Cell Biol. 5:143–148. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim BS, Bae E, Kim YJ, et al: Combination
of SK-7041, one of novel histone deacetylase inhibitors, and
STI571-induced synergistic apoptosis in chronic myeloid leukemia.
Anticancer Drugs. 18:641–647. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fang G, Kim CN, Perkins CL, Ramadevi N,
Winton E, Wittmann S and Bhalla KN: CGP57148B (STI-571) induces
differentiation and apoptosis and sensitizes Bcr-Abl-positive human
leukemia cells to apoptosis due to antileukemic drugs. Blood.
96:2246–2253. 2000.
|
|
25
|
Kawano T, Horiguchi-Yamada J, Iwase S,
Akiyama M, Furukawa Y, Kan Y and Yamada H: Depsipeptide enhances
imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and
ectopic expression of cyclin D1, c-Myc or active MEK abrogates this
effect. Anticancer Res. 24:2705–2712. 2004.
|
